Hankang Capital | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Hankang Capital/Activity

Hankang Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

4 investments· MAY 2025 – AUG 2026Show all

Investment

Participated as an existing investor in AusperBio's $120M Series C financing to advance chronic Hepatitis B functional-cure therapy AHB-137.

AusperBio

AusperBio Hankang Capital

biospace.comAUG 27, 2026

AUG 27, 2026

Investment

Led Leadingtac Pharmaceutical's RMB 200M+ (~$28M) Series B financing for its targeted protein degradation (TPD) drug pipeline, with Partner Dr. Lin Kan representing the firm.

Leadingtac Pharmaceutical

Leadingtac Pharmaceutical Hankang Capital

en.leadingtac.comDEC 18, 2025

DEC 18, 2025

Investment

Participated in VelaVigo's over $60M Pre-A+ financing round for antibody/ADC discovery and development, led by Shunwei Capital and Everest VC.

VelaVigo

VelaVigo Hankang Capital

hlcfund.comJUL 29, 2025

JUL 29, 2025

Investment

Participated in AusperBio's $50M Series B+ financing round alongside Sherpa Capital.

AusperBio

AusperBio Hankang Capital

ausperbio.comMAY 2025

MAY 2025

Milestone

Portfolio company VelaVigo announced a second out-licensing deal for a first-in-class bispecific antibody, validating its discovery platform.

VelaVigo

VelaVigo Hankang Capital

prnewswire.comAPR 2025

APR 2025

Investment

Returning investor in Hangzhou Highlightll Pharmaceutical's Pre-Series C financing, led by Huajin Capital, Bayland Capital, and Infinity Capital.

Highlightll Pharma

Highlightll Pharma Hankang Capital

flcube.comJAN 6, 2025

JAN 6, 2025